Summary & Overview
HCPCS Level II J9098: Injection, cytarabine liposome, 10 mg
HCPCS Level II code J9098 denotes a 10 mg injectable dose of cytarabine liposome, a chemotherapeutic agent used in oncology care. Nationally, accurate coding of specialty injectable drugs like cytarabine liposome affects drug utilization tracking, payer coverage determinations, and facility billing for outpatient infusion services. The code indicates a specific packaged drug product rather than an administration procedure.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use. The publication summarizes benchmarks and coverage considerations relevant to payers and providers, highlights common billing modifiers and service line implications, and outlines areas where policy updates or prior authorization practices commonly intersect with specialty oncology drugs.
This summary is intended for a national audience including billing professionals, revenue cycle managers, and oncology clinical administrators who need a clear reference for identifying the code, understanding its clinical role, and situating it within payer coverage discussions. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9098 represents Injection, cytarabine liposome, 10 mg. This code describes a parenteral chemotherapy agent formulation delivered as an injectable product.
Service type: Chemotherapy injection/oncology drug administration
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory acute myeloid leukemia (AML) or other hematologic malignancy for which liposomal cytarabine is indicated. The patient presents to an outpatient infusion center or inpatient oncology unit for chemotherapy administration. A hematologist-oncologist prescribes J9098 (injection, cytarabine liposome, 10 mg) with dosing based on body surface area and disease protocol. Nursing performs pre-infusion assessment including vitals, review of recent labs (complete blood count, renal and hepatic panels), and verification of medication, dose, and consent. Pharmacy compounds the liposomal cytarabine under aseptic technique and delivers it for administration. The infusion is typically given via intravenous line or central venous access with appropriate supportive care (antiemetics, hydration) and monitoring for myelosuppression, infusion reactions, and organ toxicity. Documentation includes indication, dose, lot number, route, site of administration, start and stop times, infusion reactions, and any administered pre/post medications. Billing uses HCPCS Level II code J9098 for the drug supply; appropriate CPT procedure and administration codes are billed separately according to the insertion or use of vascular access and the setting of service. Common payors for authorization and claims processing include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|